A New Way To Target Metastatic Cancer

A new selective delivery platform directs treatment to cancer cells while reducing exposure to healthy tissue.

Engineered protein particles travel through the bloodstream and accumulate in lymph nodes, where cancer often spreads.

The particle uses a two-step design: a targeting coating and a trigger that opens in the cancer environment to release therapy.

It releases an immune-activating antibody that removes a key cancer defense mechanism.

The platform could be expanded to deliver other antibody drugs and gene-based therapies.